TGV Sraac manufactures industrial chemicals including caustic soda, caustic potash, and chloromethanes, alongside castor oil derivatives and fatty acids, primarily serving the aluminum, textile, and pharmaceutical industries.
The company operates in a commodity chemical market where the primary advantage is cost efficiency through scale and captive power. While the shift toward solar power and internal chlorine consumption for chloromethanes provides some cost insulation, the lack of durable pricing power is evidenced by significant margin compression during cyclical downturns.
Earnings are primarily reinvested into capacity expansions for chloromethanes and significant captive solar power projects to reduce energy costs. Dividend payouts have remained consistent at 10% despite volatile earnings, showing a commitment to base-level shareholder returns.
Five years out, the investment collapsed as the commodity cycle turned viciously against caustic soda and chloromethanes while energy costs spiked. The captive solar projects failed to offset the loss of the Bellary power plant's revenue stream, and the massive related-party transactions—once seen as routine—became a siphon for remaining liquidity during the downturn. As margins compressed toward zero, the lack of pricing power left the company unable to service its maintenance capex, and the aging board failed to pivot the strategy, leading to a permanent impairment of capital.
RichFakir rates TGV Sraac Ltd's business quality as mediocre — 46/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, TGV Sraac Ltd is trading about 6% above our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on TGV Sraac Ltd is: Not rated. A mediocre business at a fair price — it does not make our shortlist right now.
RichFakir's educational estimate of TGV Sraac Ltd's fair value is about ₹104 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →